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Background: Hemodynamic abnormalities and acute kidney injury (AKI) are often
present in infected cirrhotic patients. Hence, an early diagnosis of AKI is necessary,
which might require the validation of new predictors as the determinations of
urinary neutrophil gelatinase-associated lipocalin (uNGAL) and cardiac output.
Methods: We evaluated 18 infected cirrhotic patients subdivided into two groups
at admission (0 hours). In Group I, we collected urine samples at 0 hours, 6 hours,
24 hours, and 48 hours for uNGAL and fractional excretion of sodium determina-
tions. In Group II, we measured cardiac output using echocardiography.
Results: The age of patients was 55.071.9 years, and 11 patients were males. The
Model for End-Stage Liver Disease score was 2171, whereas the Child–Pugh score
was C in 11 patients and B in 7 patients. Both patients in Group I and Group II
showed similar baseline characteristics. In Group I, we diagnosed AKI in 5 of 9
patients, and the mean time to this diagnosis by measuring serum creatinine was
5.4 days. Patients with AKI showed higher uNGAL levels than those without AKI
from 6 hours to 48 hours. The best accuracy using the cutoff values of 68 ng uNGAL/mg
creatinine was achieved at 48 hours when we distinguished patients with and without
AKI in all cases. In Group II, we diagnosed AKI in 4 of 9 patients, and cardiac output was
signiﬁcantly higher in patients who developed AKI at 0 hours.
Conclusion: Both uNGAL and cardiac output determinations allow the prediction of
AKI in infected cirrhotic patients earlier than increments in serum creatinine.
Copyright & 2015. The Korean Society of Nephrology. Published by Elsevier. This is an
open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Bacterial infections are responsible for 30–50% of hospital
admissions among patients with cirrhosis [1]. Infection sites15. The Korean Society of Nep
.org/licenses/by-nc-nd/4.0/).
squisa Básica (LIM-12),
Medicina da Universidade
10, 01246-903 São Paulo,include the peritoneum, urinary tract, lungs, and dermis [2].
Patients with cirrhosis and bacterial infection have a high
incidence of acute kidney injury (AKI), which occurs in about
one-third of these patients. The mortality rate by bacterial-
induced infection AKI ranges from 15% to 78% depending on
the site of infection and stage of cirrhosis [1].
Early recognition and treatment of such a severe complica-
tion in cirrhotic patients is correlated with better clinical
outcomes [3]. In the past three decades, treatment with
suitable antibiotics and large-volume albumin infusion in thehrology. Published by Elsevier. This is an open access article under the
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rates from 80% to 20%. In addition, AKI development also
reduced by almost 70% in these patients [3,4]. However, the
beneﬁt of such a treatment may be restricted to high-risk
patients with serum creatinine (SCr) 41 mg/dL and/or serum
bilirubin 44 mg/dL [5–7].
Although SCr and fractional excretion of sodium (FENa)
have been used to identify patients with AKI, there is great
concern about their limitations. Besides being a marker of
renal function rather than kidney injury, SCr may be under-
estimated in cirrhotic patients because of their hypervolemic
state, low muscular mass, and decreased hepatic production of
creatinine [8]. Furthermore, SCr may take up to 2 days to
increase after kidney injury. For these reasons, using SCr to
identify high-risk patients among those with cirrhosis and
bacterial infection may overlook a signiﬁcant number of
patients.
Urinary neutrophil gelatinase-associated lipocalin (uNGAL) has
been used as a better predictor of AKI than SCr and FENa [9].
NGAL is a 22-kDa peptide expressed by activated neutrophils and
kidney tubular injured cells. It is eliminated in urine, and its
dosage may rise 6–48 hours before SCr in patients with AKI.
Another potential marker of AKI development in patients
with cirrhosis is cardiac output. A previous study demon-
strated that low cardiac output in cirrhotic individuals in the
outpatient setting predicted AKI development in the subse-
quent year [10]. In addition, Ruiz-del-Arbol et al [11] also
reported similar ﬁndings in patients admitted to hospital with
tense ascites without bacterial infections. However, no studies
to date have correlated cardiac output at admission and AKI
development during bacterial infection in cirrhosis.
Thus, we hypothesized that uNGAL and cardiac output may
be early predictors of AKI in patients with cirrhosis and
bacterial infection.Methods
Study patients
We conducted this study at the Hospital das Clínicas da
Faculdade de Medicina da Universidade de São Paulo, which is
a tertiary care hospital in Sao Paulo, Brazil, from November
2011 to June 2012. We evaluated 18 consecutive patients in
whom cirrhosis and bacterial infection were present at admis-
sion. We diagnosed cirrhosis by liver biopsy or a combination
of clinical, laboratory, radiological, and endoscopic data, and
we deﬁned bacterial infection according to the International
Sepsis Deﬁnitions Conference 2001 [12]. We excluded patients
with severe comorbidities, septic shock, chronic kidney
disease, use of nephrotoxic drugs, hemodialysis treatment, or
pre-existing liver transplantation.
All patients had clinical and laboratory data collected at
admission (0 hours) to evaluate hepatic and renal functions at
that time. Moreover, we measured SCr daily during hospital
stay to AKI diagnosis. We deﬁned AKI as the conventional
criteria used in cirrhotic patients (i.e., a rise in SCr of at least
50% from baseline to a ﬁnal value above 1.5 mg/dL) [13].
In our institution, the treatments of patients with cirrhosis
and AKI are as follows: (1) patients with suspected prerenal
azotemia receive resuscitation volume with crystalloids or
albumin according to the physician's decision and (2) patients
with suspected hepatorenal syndrome receive albumin 1 g/kg/dfor 2 days and, if renal function does not improve, we prescribe
terlipressin in combination with albumin infusion.
We divided the patients into two groups: those for uNGAL
measurements (Group I) and those for cardiac output study
(Group II).
In Group I, we collected urine samples at 0 hours, 6 hours, 24
hours, and 48 hours for NGAL and FENa determinations. We
measured uNGAL in duplicate using an enzyme-linked immuno-
sorbant assay kit (NGAL ELISA human kit 036, BioPorto
Diagnostics, Gentoft, Denmark), and we used the cutoff values
of uNGAL of 68 ng and 130 ng NGAL/mg creatinine in
agreement with previous studies [14,15]. We also quantiﬁed
urinary and plasma sodium for FENa determinations using
ﬂame photometry (model FC 280, CELM, São Paulo, SP, Brazil).
In Group II, we measured outﬂow tract area of left ventricle,
velocity-time integral, and heart rate by echocardiography at
admission, and we calculated cardiac output using the formula:
cardiac output¼ left ventricle outﬂow tract area velocity time
integralheart rate
Statistical analysis
We expressed data as mean7standard error of the mean.
We used unpaired Student t test to compare baseline char-
acteristics of patients in Group I with those of Group II and
between parameters of patients who developed AKI or not.
Values of Po0.05 were considered signiﬁcant.
Ethical statement
The Research Ethics Committee of our institution (Comissão
de Ética para Análise de Projetos de Pesquisa—CAPPesq, da
Diretoria Clínica do Hospital das Clínicas da Faculdade de
Medicina da Universidade de São Paulo) approved this study,
which follows ethical standards established by the Declaration
of Helsinki. All patients wrote and signed an informed consent
before enrollment in the study.Results
Baseline clinical characteristics
Table 1 shows the baseline clinical characteristics of
infected cirrhotic patients in Group I and Group II at hospital
admission. The mean age of patients was 55.071.9 years.
There were 11 (61%) males and 7 (39%) females. The etiology of
cirrhosis was alcohol in 6 patients (33%), cryptogenic in 4
patients (22%), alcohol associated with hepatitis C in 3 patients
(17%), hepatitis C in 2 patients (11%), and other etiologies in
3 (17%) patients. The Child–Pugh score was C in 11 (61%)
patients and B in 7 (39%) patients, and Model for End-Stage
Liver Disease (MELD) score was 2171. Furthermore, the
baseline clinical characteristics of patients in Group I were
similar to those of patients in Group II.
Although we found similar MELD score in both groups,
MELD score was higher in patients who developed AKI than
those patients who did not (2671 vs. 1672, P¼0.001), at
hospital admission. However, both groups showed similar
values of C-reactive protein that were 61719 mg/L vs.
40712 mg/L in patients with and without AKI, respectively.
As expected, SCr did not allow predicting AKI at 0 hours. SCr
values were 1.9570.37 mg/dL and 1.2270.29 mg/dL, P¼0.14
Table 1. Baseline clinical characteristics of infected cirrhotic patients in Group I and Group II at admission
Group Pt Sex Age
(y)
Infection
site
CRP
(mg/L)
SCr (mg/dL) MELD
score
uNGAL
ngNGAL/mg
creatinine
CO AKI
I 1 F 66 SBP 33.1 0.74 15 19.2 – No
I 2 F 48 SBPþskin 21.7 0.74 23 42.8 – Yes
I 3 M 51 SBP 104.7 0.58 9 54.8 – No
I 4 M 44 SBP 22.6 1.04 26 26.8 – No
I 5 M 63 SBP 155.5 3.77 29 152.6 – Yes
I 6 F 64 SeBP 94.1 1.22 20 89.7 – Yes
I 7 M 51 SBP 47.8 3.35 25 100.5 – No
I 8 M 53 SBP 84.4 3.21 32 296.0 – Yes
I 9 M 50 UTIþskin 4.0 2.28 23 264.0 – Yes
II 10 M 63 Skin 26.3 1.11 24 – 9.7 Yes
II 11 M 39 Cholecystitis — 0.74 13 – 4.4 No
II 12 M 63 Cholangitis 97.2 1.75 30 – 9.9 Yes
II 13 F 63 SBP 75.3 0.82 13 – 3.7 No
II 14 F 53 UTI 2.7 1.02 17 – 4.1 No
II 15 M 49 SBP 27.4 1.86 18 – 7.7 No
II 16 F 62 Skin 3.7 0.83 9 – 8.5 No
II 17 F 56 UTI 3.1 0.76 22 – 8.1 Yes
II 18 M 61 UTI — 2.75 29 – 8.4 Yes
Mean 5572 50711 1.5970.25 2171
AKI, acute kidney injury; CRP, C-reactive protein; CO, cardiac output; F, female; M, male; MELD, Model for End-Stage Liver Disease; Pt, patients; SBP,
spontaneous bacterial peritonitis; SCr, serum creatinine; SeBP, secondary bacterial peritonitis; uNGAL, urinary neutrophil gelatinase-associated
lipocalin; UTI, urinary tract infection.
Table 2. Urinary NGAL and FENa of infected cirrhotic patients who
developed AKI or not at different evaluation times
Time (h) AKI
(n¼5)
No AKI
(n¼4)
P
uNGAL
(ng NGAL/mg Cr)
0 169749 50718 0.078
6 143733 48713 0.047
24 141733 30710 0.025
48 188729 33724 0.026
FENa (%)
0 0.8070.36 0.1270.06 0.140
6 1.2470.58 0.3270.13 0.211
24 1.2370.68 0.2970.15 0.413
48 0.6170.27 0.3270.27 0.569
Data are expressed as mean ± standard error of the mean.
AKI, acute kidney injury; FENa, fractional excretion of sodium; uNGAL,
urinary neutrophil gelatinase-associated lipocalin.
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who developed AKI, six of nine patients fulﬁlled hepatorenal
syndrome criteria, one had AKI secondary to nephrotoxic drug
(contrastþpolymixin) whose prescription was done after hospital
admission, one probably had acute tubular necrosis secondary to
a hemorrhagic shock, and one was thought to have transitory AKI
related to infection.
The role of uNGAL in predicting AKI
In Group I, 5 of 9 patients (56%) developed AKI in mean
time of 5.4 days that was associated with 100% in-hospital
mortality rate. As shown in Table 2 and illustrated in Fig. 1,
uNGAL was signiﬁcantly higher in patients with AKI than in
those without AKI at 6 hours, 24 hours, and 48 hours. We also
observed that the cutoff values of 68 ng NGAL/mg creatinine
stratiﬁed better than 130 ng NGAL/mg creatinine with an
accuracy of 77.8% to predict AKI (sensitivity, 80%; speciﬁcity,
75%; positive predictive value, 80%; and negative predictive
value, 75%) at 0 hours. The best accuracy using uNGAL was
achieved at 48 hours, which distinguished patients with and
without AKI in 100% of cases. However, increments in SCr only
occurred after 72 hours, as illustrated in Fig. 2.
With regard to FENa, we did not ﬁnd any statistical
signiﬁcance between patients with and without AKI, as shown
in Table 2.
The role of cardiac output in predicting AKI
In Group II, 4 of 9 patients (44%) developed AKI, and these
patients showed hyponatremia and higher cardiac output,
heart rate, as well as MELD and Child–Pugh scores than those
patients who did not develop AKI at hospital admission, as
shown in Table 3. The fact that patients who developed AKIshowed high MELD and Child–Pugh scores allowed us to
diagnose worse liver function in these patients at hospital
admission. In addition, only cardiac output levels showed
signiﬁcant increments to be considered a reliable predictor of
AKI at hospital admission (Fig. 3). With regard to mean arterial
blood pressure, SCr, serum albumin, and serum bilirubin, we
did not ﬁnd any statistical difference between patients who
developed AKI or not (Table 3).Discussion
Our study shows that both uNGAL and cardiac output
determinations allow the prediction of AKI in infected cirrhotic
patients earlier than increments in SCr. It is noteworthy that
uNGAL measured as soon as 6 hours from hospital admission
was already accurate to predict AKI development, as opposed
to SCr. This biomarker allowed AKI diagnosis in a mean time of
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Figure 1. Time course of urinary NGAL. The values of urinary NGAL measured at 0 hours, 6 hours, 24 hours, and 48 hours in infected cirrhotic
patients who developed acute kidney injury (◆) or not (■). *P o 0.05 vs. patients without acute kidney injury. NGAL, neutrophil gelatinase-associated
lipocalin.
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Figure 2. Urinary NGAL and SCr. The levels of urinary NGAL (●)
and SCr (▄) in infected cirrhotic patients who developed AKI during
hospitalization. AKI, acute kidney injury; NGAL, neutrophil gelatinase-
associated lipocalin; SCr, serum creatinine.
Table 3. Comparison of clinical characteristics from infected cir-
rhotic patients (Group II) at admission
Patients
with AKI
Patients
without AKI
P
(n¼5) (n¼4)
SCr (mg/dL) 1.5970.44 1.0570.21 0.270
Plasma Na+ (mEq/L) 132.572.2 141.071.3 0.010
Serum albumin (g/dL) 2.2070.27 2.7270.28 0.231
Serum bilirubin (mg/dL) 10.0675.42 1.8170.34 0.128
INR (sec) 2.2270.26 1.4270.11 0.016
MELD score 26.271.9 14.071.6 0.002
Child–Pugh score 13.5070.64 7.8070.58 0.001
Heart rate (beats/min) 97.073.3 77.076.2 0.034
Cardiac output (L/min) 9.0270.45 5.6871.00 0.027
Mean blood pressure (mmHg) 93.074.1 89.479.6 0.763
Data are expressed as mean ± standard error of the mean. *Po0.05,
†Po0.01, ‡Po0.001 versus patients without acute kidney injury.
AKI, acute kidney injury; INR, international normalized ratio; MELD,
Model for End-Stage Liver Disease; SCr, serum creatinine.
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predictor of AKI. Furthermore, other studies show the impor-
tance of uNGAL to distinguish the patients with transient AKI
from those with intrinsic AKI during sepsis [16].
Moreover, in a recent experimental study, we demonstrated
that only uNGAL was able to predict AKI [17]. We treated
normal and hypercholesterolemic rats with acute infusion of
angiotensin II, and we observed a reduction in glomerular
ﬁltration rate and increments in diuresis and natriuresis in
both groups. However, we found renal damage with a histo-
logic examination only in the kidneys of hypercholesterolemic
rats, and in the same group, we have also observed increments
in uNGAL values.
A high cardiac output measured at admission also predicted
AKI development during hospital stay in our patients. Krag
et al [18] proposed a cardiorenal link in advanced cirrhosis,
especially in those cirrhotic patients with bacterial infection in
a recent publication. However, our ﬁndings concerning this
parameter differ from other data from cirrhotic individuals in
the outpatient setting and from patients without bacterial
infection [10,11]. We would like to point out that our cirrhoticpatients evaluated in the present study showed serious infec-
tions. Thus, they were more likely to develop AKI associated
with a hyperdynamic circulation rather than a cause–effect
relationship. Furthermore, we also conﬁrmed that patients
with high scores of end-stage chronic liver disease were more
susceptible to developing AKI.
Cardiac output measurement using echocardiography is a
readily available method that may be performed as a point-of-
care test by any appropriately trained clinician. It may become a
good option to identify patients at high risk of AKI development,
especially in low-income institutions, where AKI biomarkers such
as uNGAL are less likely to be available in the near future.
Our study had some limitations. First, we studied a small
number of patients. Nevertheless, we could ﬁnd a result with
statistical signiﬁcance. However, our number of patients
did not allow a multivariate analysis, which might show that
increases in urine NGAL or increases in cardiac output could
independently predict AKI. Further studies with a higher
number of patients are warranted to conﬁrm our ﬁndings
with regard to the best cutoffs of uNGAL, especially, and test
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Figure 3. Comparisons between patients (Group II) with and without AKI. (A) The levels of SCr. (B) MELD score. (C) The levels of uNGAL. (D) The
levels of cardiac output. AKI, acute kidney injury; MELD, Model for End-Stage Liver Disease; NGAL, neutrophil gelatinase-associated lipocalin; N.S., not
signiﬁcant; SCr, serum creatinine.
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esting to test if uNGAL can predict AKI regardless of severity of
infection in cirrhotic patients, as some studies suggest that its
levels are inﬂuenced by the severity of inﬂammation in other
scenarios [19]. Second, we used an AKI deﬁnition that differs
from new deﬁnitions such as Acute Kidney Injury Network
(AKIN) and Kidney Disease: Improving Global Outcomes
(KDIGO) criteria. Although we recognize the importance of
these new deﬁnitions, we decided to use the conventional
deﬁnition of AKI in cirrhosis because AKIN and KDIGO had not
been adequately validated in cirrhotic patients when the study
was designed.
In a recent study, Santos et al [20] showed acute renal
dysfunction in sugarcane harvesting workers. These indivi-
duals were healthy men and might have a diagnosis of AKI if
we use KDIGO criteria, but if we use AKIN criteria, we might
not diagnose AKI. Furthermore, Sutherland et al [21] have also
concluded that a single and universal AKI deﬁnition is required
in pediatric population as well because pediatric version of
Risk, Injury, Failure, Loss of kidney function, and End-stage
kidney disease criteria did not show the same incidence of AKI
when applied. These ﬁndings may reinforce the need for a
special validation with cirrhotic patients.
We have also found high MELD and Child–Pugh scores at
hospital admission in patients who developed AKI, but C-reactive
protein values were similar in patients with and without AKI. A
high MELD and Child–Pugh scores mean severe liver dysfunction
in these patients. However, MELD score includes SCr in its formula,
which has many limitations as described previously. Takentogether, these results may reinforce the need to ﬁnd an easy
tool to predict AKI in infected cirrhotic patients as cardiac output
measurement. Thus, a special treatment may be prescribed as
soon as possible to reduce mortality rate in these cases.
In conclusion, both uNGAL and cardiac output determina-
tions allow the prediction of AKI in patients with cirrhosis and
bacterial infection earlier than increments in SCr.Conﬂicts of interest
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